Back to Search
Start Over
EVALUATION OF ANTI DIABETIC DRUG ALOGLIPTIN FOR THE TREATMENT OF OBESITY IN RATS
- Source :
- Journal of Drug Delivery and Therapeutics. 8:209-216
- Publication Year :
- 2018
- Publisher :
- Society of Pharmaceutical Tecnocrats, 2018.
-
Abstract
- Obesity is a complex disease caused by the interaction of a myriad of genetic, dietary, lifestyle, and environmental factors, which favors a chronic positive energy balance, and leads to increased body fat mass. The incidence of obesity is rising at an alarming rate and is becoming a major public health concern with incalculable social costs. Indeed, obesity facilitates the development of metabolic disorders such as diabetes, hypertension, and cardiovascular diseases in addition to chronic diseases such as stroke, osteoarthritis, sleep apnea, some cancers, and inflammation based pathologies. Standard reference Sibutramine produced a significant anti obesity activity in HFD induced obesity in rats. Alogliptin with medium and high doses exhibited a significant anti obesity activity by reducing the body weight, food intake, organ and fat pads weight and serum GLU, CHO, TRG, LDL and VLDL cholesterol levels with an increased HDL levels in HFD induced obesity models in rats. Keywords: Alogliptin, Anti-obesity, Anti-diabetics, DPP-4
Details
- ISSN :
- 22501177
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Journal of Drug Delivery and Therapeutics
- Accession number :
- edsair.doi...........45a90ff0f31a66ffc691441960ce8e1b